# Champions Oncology

> Champions Oncology is a global oncology contract research organization selling preclinical studies, analytical services, tumor-model data licenses and Lumin bioinformatics subscriptions to pharmaceutical and biotechnology companies. Its TumorGraft platform connects patient-derived cancer models with molecular characterization and treatment-response data.

- **Founded:** 2007
- **Headquarters:** Hackensack, United States
- **Founders:** David Sidransky (Founder; former chairman; lead director)
- **Products:** TumorGraft PDX models, TumorGraft3D, Lumin Bioinformatics, Radiopharmaceutical development, Immuno-oncology and hematological platforms
- **Notable:** Built a clinically annotated living tumor-model bank; the current PDX page advertises over 1,500 models., Reported record FY2026 annual revenue of $59.4 million., Added in-house SPECT/CT imaging to its radiopharmaceutical workflow in 2026.

## Products & services

- **TumorGraft PDX models** — Patient-derived xenograft models for efficacy, resistance, combination and biomarker studies; the current PDX page advertises over 1,500 models.
- **TumorGraft3D** — PDX-derived three-dimensional tumor cultures for ex vivo screening, with matched in vivo models available.
- **Lumin Bioinformatics** — Subscription software for model selection, multi-omic analysis and visualization, combining proprietary oncology data with public datasets.
- **Radiopharmaceutical development** — Radiolabeling, quality control, biodistribution, efficacy studies and in-house SPECT/CT imaging. Imaging expansion announced in September 2026.
- **Immuno-oncology and hematological platforms** — Humanized and syngeneic mouse models, hematological models and ex vivo screens selected for the biological question.
- **Analytical and clinical specialty testing** — Flow cytometry, histology/IHC, sequencing and other assays; the FY2026 filing reports reduced investment in flow cytometry.
- **PDX data licensing** — Contractual access to selected proprietary tumor-model datasets, separate from Lumin subscriptions.
- **KRAS preclinical platform** — Integrates tumor models, response data and molecular profiling for response, resistance and combination research.

## Achievements

- Built a clinically annotated living tumor-model bank; the current PDX page advertises over 1,500 models.
- Reported record FY2026 annual revenue of $59.4 million.
- Added in-house SPECT/CT imaging to its radiopharmaceutical workflow in 2026.
- Maintains public bioinformatics code and Lumin Workspaces documentation on GitHub.

## Latest updates

- **2026-09** — Reported $15.2 million revenue for the quarter ended July 31, 2026, up 8.8% year over year; oncology services margin was 51% and adjusted EBITDA was $671,000.
- **2026-09** — Announced integrated in-house SPECT/CT imaging for radiopharmaceutical studies; the press index dates the announcement September 1, while the article page also displays August 31.
- **2026-07** — FY2026 revenue reached $59.425 million; the filing also showed a $1.175 million net loss and reduced data licensing revenue.
- **2025-08** — Rob Brainin became CEO effective August 25; Ronnie Morris moved to Executive Chair.

## Links

- Website: https://www.championsoncology.com/
- LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
- Twitter/X: https://twitter.com/ChampionsOncol1
- GitHub: https://github.com/Champions-Oncology
- YouTube: https://www.youtube.com/c/ChampionsOncology/videos
- Instagram: https://www.instagram.com/championsoncology/
- Facebook: https://www.facebook.com/championsoncology

---

Profile page: https://yespress.io/champions-oncology
Published by YesPress — https://yespress.io
Last updated: 2026-10-24